SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

Rhea-AI Summary

SCYNEXIS (NASDAQ: SCYX) announced presentations on its second‑generation fungerp, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), Jan 28–30, 2026, in Las Vegas.

The company said SCY-247 showed potent in vitro and in vivo antifungal activity, a favorable safety profile, and supportive pharmacokinetics in clinical investigations to date. Oral presentation: Jan 29, 9:00–10:30am; poster: Jan 30. Materials will be posted in the company’s Publications and Presentations section after the meeting.

News Market Reaction

-3.18%

2 alerts

-3.18% News Effect

-$1M Valuation Impact

$34M Market Cap

0.0x Rel. Volume

On the day this news was published, SCYX declined 3.18%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $34M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: January 28–30, 2026 Oral session date: January 29, 2026 Oral session time: 9:00–10:30am +1 more

4 metrics

Conference dates January 28–30, 2026 IMARI meeting dates in Las Vegas

Oral session date January 29, 2026 Plenary session on new antimicrobial agents

Oral session time 9:00–10:30am Plenary session featuring SCY-247 presentation

Poster session date January 30, 2026 Poster presentation of SCY-247 data at IMARI

Market Reality Check

Price: $0.7110 Vol: Volume 376,182 is below t...

normal vol

$0.7110 Last Close

Volume Volume 376,182 is below the 20-day average of 513,579, suggesting limited pre-news positioning. normal

Technical Price at $0.80 is trading slightly above the $0.79 200-day moving average, near longer-term trend levels.

Peers on Argus

Peer moves are mixed, with names like CPIX at +2.19% and RMTI at +4.55%, while I...

1 Down

Peer moves are mixed, with names like CPIX at +2.19% and RMTI at +4.55%, while IXHL and AYTU are down. Momentum scanner shows only FLGC moving sharply lower, indicating today’s setup appears stock-specific rather than a coordinated sector move.

Historical Context

5 past events · Latest: Jan 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 21	Regulatory designations	Positive	+4.0%	FDA QIDP and Fast Track designations granted for SCY-247.
Dec 22	Listing compliance	Negative	-2.3%	Nasdaq grants 180-day extension to regain minimum bid compliance.
Nov 19	Asset transfer	Positive	+1.8%	Completion of BREXAFEMME NDA transfer to GSK with milestone potential.
Nov 17	Collaboration funding	Positive	-1.4%	Federal five-year CETR grant supporting next-generation fungerp projects.
Nov 05	Earnings and update	Positive	+0.1%	Q3 2025 results, GSK payment, and multi-year cash runway disclosure.

Pattern Detected

Recent news reactions mostly aligned with headline tone, with one negative price move on otherwise positive collaboration funding news.

Recent Company History

Over the last few months, SCYNEXIS highlighted regulatory, strategic, and financial milestones. FDA granted QIDP and Fast Track for SCY-247 on Jan 21, 2026, which saw a positive price reaction. Nasdaq granted a bid-price compliance extension, while GSK-related deals offered non-dilutive cash and potential milestones. Earlier, federal funding supported next-generation fungerp research. Today’s IMARI presentations continue the narrative of advancing SCY-247 against resistant fungi.

Market Pulse Summary

This announcement highlights SCY-247’s potent antifungal activity and favorable safety and pharmacok...

Analysis

This announcement highlights SCY-247’s potent antifungal activity and favorable safety and pharmacokinetics, showcased at the IMARI meeting from January 28–30, 2026. It reinforces the company’s focus on drug-resistant fungal infections and builds on prior QIDP and Fast Track designations. Investors may watch for upcoming Phase 1 and Phase 2 data, progress on GSK-related milestones, and continued efforts to address prior Nasdaq minimum bid-price compliance challenges.

Key Terms

in vitro, in vivo, pharmacokinetics, antifungal, +1 more

5 terms

in vitro medical

"The potent in vitro and in vivo antifungal activity of our second-generation fungerp..."

In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

in vivo medical

"The potent in vitro and in vivo antifungal activity of our second-generation fungerp..."

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

pharmacokinetics medical

"...favorable safety profile and pharmacokinetics observed in clinical investigations to date..."

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

antifungal medical

"The potent in vitro and in vivo antifungal activity of our second-generation fungerp, SCY-247..."

Antifungal describes a drug, treatment, or product that prevents the growth of or kills fungi, including yeasts and molds — like a weed killer or mold cleaner but for fungal infections in people, animals, or surfaces. Investors care because antifungal products involve research, regulatory approval, patent protection, manufacturing and sales dynamics that affect revenue potential and risk; clinical trial results, approval decisions, or safety concerns can materially change a company’s valuation.

antimicrobial resistance medical

"...meeting focused on addressing the significant threat of antimicrobial resistance..."

Antimicrobial resistance is when microbes such as bacteria, viruses or fungi evolve so that medicines meant to kill them no longer work — like a lock changing so the old key no longer fits. For investors, this increases demand and cost for new treatments, prolongs hospital stays, prompts tougher regulation and can shrink sales of once-effective drugs, affecting pharmaceutical revenues, R&D spending and broader healthcare risk.

AI-generated analysis. Not financial advice.

This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutions

JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), which is taking place from January 28 to 30, 2026, in Las Vegas, Nevada.

“We are pleased to participate in this important inaugural multidisciplinary meeting focused on addressing the significant threat of antimicrobial resistance,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. “The potent in vitro and in vivo antifungal activity of our second-generation fungerp, SCY-247, together with the favorable safety profile and pharmacokinetics observed in clinical investigations to date, position this novel agent as a potentially critical weapon in the fight against deadly fungal infections, including those resistant to existing antifungal therapies. We look forward to sharing our development progress with the scientific community at IMARI, an especially timely conference given the growing recognition of the serious impact to human health posed by antifungal resistance.”

An oral presentation of SCY-247 highlighting its antifungal activity against resistant fungi, will be included in the Plenary session “New Antimicrobial Agents in The Pipeline: Early Clinical Development” on January 29 from 9-10:30am and will also be displayed in the Poster session on January 30^th. The presentation and poster will be posted in the Publications and Presentations section of the Company’s website after the meeting.

IMARI is a joint conference organized by the American Society for Microbiology (ASM) and the Infectious Diseases Society of America (IDSA) that brings together researchers, clinicians, industry leaders and policymakers to address one of the greatest challenges in modern medicine: antimicrobial resistance.

About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) has approved BREXAFEMME^® (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC. The second generation fungerp SCY-247 is currently in clinical stages of development and has received QIDP and Fast Track designation from the FDA. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phases. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: The characteristics of SCY-247 and its potential to be a key contributor in the fight against deadly fungal infections, including those resistant to existing antifungal therapies. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 12, 2025, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: 
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: 917-734-7387
ikoffler@lifesciadvisors.com

FAQ

What will SCYNEXIS (SCYX) present about SCY-247 at IMARI on January 29, 2026?

SCYNEXIS will give an oral presentation on Jan 29 highlighting SCY-247’s antifungal activity against resistant fungi. According to the company, the talk is part of the Plenary session “New Antimicrobial Agents in The Pipeline: Early Clinical Development.”

When and where will the SCY-247 poster by SCYNEXIS (SCYX) be displayed at IMARI?

The SCY-247 poster will be displayed on Jan 30, 2026, during the IMARI Poster session in Las Vegas. According to the company, the poster complements the Jan 29 oral presentation and will later be posted online.

What clinical and preclinical attributes of SCY-247 will SCYNEXIS (SCYX) highlight at IMARI?

SCYNEXIS will highlight potent in vitro and in vivo antifungal activity, favorable safety, and pharmacokinetics for SCY-247. According to the company, these attributes support its potential against drug-resistant fungal infections.

Will SCYNEXIS (SCYX) publish the SCY-247 IMARI materials online after the meeting?

Yes, the company said the presentation and poster will be posted in the Publications and Presentations section of its website after IMARI. This will allow investors and researchers to review the SCY-247 data shared at the conference.

What is the significance of SCY-247 data being presented at the inaugural IMARI conference for SCYNEXIS (SCYX)?

Presenting at IMARI gives SCYNEXIS visibility among researchers, clinicians, and policymakers focused on antimicrobial resistance. According to the company, the timing underscores growing concern about antifungal resistance and interest in new therapeutic options.

Which IMARI session includes SCYNEXIS’s (SCYX) SCY-247 oral presentation on January 29?

SCY-247 is scheduled in the Plenary session titled “New Antimicrobial Agents in The Pipeline: Early Clinical Development” on Jan 29 from 9:00–10:30am. According to the company, this session focuses on early clinical-stage antimicrobial programs.